DF Doctors Present Findings

Drs. Liu, Brady and Matulonis from Dana Farber, recently presented their findings on a phase III study looking at recurrent, platinum-sensitive ovarian cancer (OC) at this year's ASCO Virtual Scientific Program.

The study looked at treating recurrent OC with three different treatment options: platinum based chemo, treatment with olaparib (PARP inhibitor) or olaparib plus cediranib (anti-angiogenic).

The study did not meet its primary endpoint of progression-free survival but the authors felt that the results showed a comparable effect to the more traditional platinum based chemo. Of note however, the combination of olaparib and cediranib were more successful in patients with germ-line BRCA mutations.

To read more about the study, follow this link.